Dysregulation of the receptor activator of NF-κB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells Co-cultured with myeloma cells

Archivum Immunologiae et Therapiae Experimentalis

Volumn 58, Issue 2, 2010, Pages 153-163

  Zdzisińska, Barbara ^a   Bojarska Junak, Agnieszka ^b   Walter Croneck, Adam ^b   Kandefer Szerszeń, Martyna ^a  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Apoptosis; Bone marrow stromal cells; Multiple myeloma; OPG; RANKL

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOPROTEGERIN; ALKALINE PHOSPHATASE; HYBRID PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; RANK FC; RANK-FC; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL CULTURE; CELL INTERACTION; CELL SURVIVAL; CELL TYPE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOCLASTOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; BONE MARROW CELL; CASE CONTROL STUDY; COCULTURE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; STROMA CELL; TIME; TUMOR CELL LINE;

ADULT; AGED; ALKALINE PHOSPHATASE; APOPTOSIS; BONE MARROW CELLS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOPROTEGERIN; POLYMERASE CHAIN REACTION; RANK LIGAND; RECOMBINANT FUSION PROTEINS; SPECTROPHOTOMETRY; STROMAL CELLS; TIME FACTORS;

EID: 77952751849     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-010-0070-5     Document Type: Article

References (35)

1. I Breitkreutz MS Raab S Vallet, et al. 2008 Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma Leukemia 22 1925 1932 10.1038/leu.2008.174 18596740 1:CAS:528: DC%2BD1cXht1Cms7%2FO
2. N Calvani P Cafforio F Silvestris, et al. 2005 Functional osteoclast-like transformation of cultured human myeloma cell lines Br J Haematol 130 926 938 10.1111/j.1365-2141.2005.05710.x 16156862 1:CAS:528:DC%2BD2MXhtFegtL3J (Pubitemid 43899733)
3. BG Durie SE Salmon 1975 A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival Cancer 36 842 845 10.1002/1097-0142(197509) 36:3<842::AID-CNCR2820360303>3.0.CO;2-U 1182674 1:STN:280: DyaE28%2FktFCqtA%3D%3D
4. AN Farrugia GJ Atkins LB To, et al. 2003 Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo Cancer Res 63 5438 5445 14500379 1:CAS:528:DC%2BD3sXntleku7w%3D
5. P Fiumara V Snell Y Li, et al. 2001 Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines Blood 98 2784 2790 10.1182/blood.V98.9.2784 11675352 1:CAS:528:DC%2BD3MXotVegsbY%3D
6. N Giuliani R Bataille C Mancini, et al. 2001 Myeloma cells induce imbalance in osteoprotegerin/osteoprotegerin ligand system in the human bone marrow microenvironment Blood 98 3527 3533 10.1182/blood.V98.13.3527 11739153 1:CAS:528:DC%2BD3MXptFOjsbk%3D
7. N Giuliani S Colla F Morandi, et al. 2004 The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment Haematologica 89 1118 1123 15377473 1:CAS:528:DC%2BD2cXovFOqsbo%3D
8. N Giuliani S Colla F Morandi, et al. 2005 Lack of receptor activator of nuclear factor-kappaB ligand (RANKL) expression and functional production by human multiple myeloma cells Haematologica 90 275 278 15710592 1:CAS:528:DC%2BD2MXisVOksrY%3D
9. N Giuliani S Colla F Morandi, et al. 2005 Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast formation and differentiation Blood 106 2472 2483 10.1182/blood-2004-12-4986 15933061 1:CAS:528:DC%2BD2MXhtVKqt73K (Pubitemid 41510822)
10. U Heider C Langelotz C Jakob, et al. 2003 Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma Clin Cancer Res 9 1436 1440 12684416 1:CAS:528:DC%2BD3sXislertLg%3D
11. U Heider C Fleissner I Zavrski, et al. 2006 Bone markers in multiple myeloma Eur J Cancer 42 1544 1553 10.1016/j.ejca.2005.11.034 16765040 1:CAS:528:DC%2BD28Xns1Grt7o%3D (Pubitemid 44118764)
12. LC Hofbauer AE Heufelder 1998 Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis Eur J Endocrinol 139 152 154 10.1530/eje.0.1390152 9724069 1:CAS:528:DyaK1cXlsV2ju7o%3D
13. LC Hofbauer CR Dunstan TC Spelsberg, et al. 1998 Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenic protein-2 and cytokines Biochem Biophys Res Commun 250 776 781 10.1006/bbrc.1998.9394 9784422 1:CAS:528:DyaK1cXmsF2qtr4%3D (Pubitemid 28484803)
14. FP Lai M Cole-Sinclair WJ Cheng, et al. 2004 Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation Br J Haematol 126 192 201 10.1111/j.1365-2141.2004.05018.x 15238139 1:CAS:528:DC%2BD2cXms1yktro%3D (Pubitemid 38961937)
15. HM Lokhorst T Lamme M de Smet, et al. 1994 Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures Blood 84 2269 2277 7919345 1:STN:280:DyaK2M%2Fgt12gug%3D%3D
16. DF McDonald BH Schofield EM Prezioso, et al. 1983 Direct bone resorbing activity of murine myeloma cells Cancer Lett 19 119 124 10.1016/0304-3835(83) 90145-3 6883303 1:STN:280:DyaL3s3osVyhug%3D%3D
17. M Nagai S Kyakumoto N Sato 2000 Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation Biochem Biophys Res Commun 269 532 536 10.1006/bbrc.2000. 2314 10708588 1:CAS:528:DC%2BD3cXhsFKhsrs%3D (Pubitemid 30440335)
18. T Nakashima Y Kobayashi S Yamasaki, et al. 2000 Protein expression and functional difference of membrane bound and soluble receptor activator of NF-kappa B ligand: modulation of the expression by osteotropic factors and cytokines Biochem Biophys Res Commun 275 768 775 10.1006/bbrc.2000.3379 10973797 1:CAS:528:DC%2BD3cXmtFGlsL8%3D
19. T Okada S Akikusa H Okuno, et al. 2003 Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells Clin Exp Metastasis 20 639 646 10.1023/A:1027362507683 14669795 1:CAS:528: DC%2BD3sXos1amtrc%3D (Pubitemid 37463901)
20. 1-VCAM-1 interaction. Bone suppl:S180
21. RN Pearse EM Sordillo S Yaccoby, et al. 2001 Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression Proc Natl Acad Sci USA 98 11581 11586 10.1073/pnas.201394498 11562486 1:CAS:528:DC%2BD3MXnt12js7w%3D (Pubitemid 32928771)
22. S Roux V Meignin J Quillard, et al. 2002 RANK (receptor activator of nuclear factor-kappa B) and RANKL expression in multiple myeloma Br J Haematol 117 86 92 10.1046/j.1365-2141.2002.03417.x 11918537 1:CAS:528: DC%2BD38XjvFGlsLg%3D (Pubitemid 34304425)
23. C Seidel O Hjertner N Abildgaard, et al. 2001 Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease Blood 98 2269 2271 10.1182/blood.V98.7.2269 11568016 1:CAS:528: DC%2BD3MXnsVCht7Y%3D
24. O Sezer U Heider C Jakob, et al. 2002 Human bone marrow myeloma cells express RANKL J Clin Oncol 20 353 354 11773196
25. O Sezer U Heider I Zavrski, et al. 2003 RANK ligand and osteoprotegerin in myeloma bone disease Blood 101 2094 2098 10.1182/blood-2002-09-2684 12424190 1:CAS:528:DC%2BD3sXit1egsrc%3D (Pubitemid 36302042)
26. CM Shipman PI Croucher 2003 Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells Cancer Res 63 912 916 12615702 1:CAS:528:DC%2BD3sXhs1agtb0%3D
27. F Silvestris P Cafforio M Tucci, et al. 2003 Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease Br J Haematol 122 39 52 10.1046/j.1365-2141.2003.04374.x 12823344 1:CAS:528:DC%2BD3sXmtVGntLY%3D (Pubitemid 36819337)
28. T Standal C Seidel O Hjertner, et al. 2002 Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells Blood 100 3002 3007 10.1182/blood-2002-04-1190 12351414 1:CAS:528:DC%2BD38XotVGhtLo%3D
29. E Terpos R Szydlo JF Apperley, et al. 2003 Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index Blood 102 1064 1069 10.1182/blood-2003-02-0380 12689925 1:CAS:528:DC%2BD3sXlvFCmt7Y%3D (Pubitemid 36917805)
30. E Terpos DJ Heath A Rahemtulla, et al. 2006 Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma Br J Haematol 135 688 692 10.1111/j.1365-2141.2006.06356.x 17107351 1:CAS:528:DC%2BD2sXitl2muw%3D%3D (Pubitemid 44674080)
31. E Terpos O Sezer P Croucher, et al. 2007 Myeloma bone disease and proteasome inhibition therapies Blood 110 1098 1104 10.1182/blood-2007-03-067710 17494860 1:CAS:528:DC%2BD2sXptFKmurk%3D (Pubitemid 47281403)
32. E Terpos E Kastritis M Roussou, et al. 2008 The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis Leukemia 22 2247 2256 10.1038/leu.2008.235 18769451 1:CAS:528:DC%2BD1cXhsFWjtb7K
33. I Tinhofer R Biedermann M Krismer, et al. 2006 A role of TRAIL in killing osteoblasts by myeloma cells FASEB J 20 759 761 16436464 1:CAS:528: DC%2BD28XjtlKjtbo%3D
34. S Vitovski JS Phillips J Sayers, et al. 2007 Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways J Biol Chem 282 31601 31609 10.1074/jbc.M706078200 17702740 1:CAS:528:DC%2BD2sXhtFykurfN (Pubitemid 350044899)
35. B Zdzisińska A Bojarska-Junak A Dmoszyńska, et al. 2008 Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells Arch Immunol Ther Exp 56 207 221 10.1007/s00005-008-0022-5 1:CAS:528:DC%2BD1cXovFKqsrY%3D